Survival following lung transplantation for artificial stone silicosis relative to idiopathic pulmonary fibrosis.

Abstract

BACKGROUND:

Silicosis is a progressive lung disease resulting from the inhalation of respirable crystalline silica. Lung transplantation is the only treatment for end-stage silicosis. The aim of this study was to analyze the survival experience following lung transplantation among patients with silicosis.

METHODS:

We reviewed data for all patients who underwent lung transplantation for silicosis and a matched group undergoing lung transplantation for idiopathic pulmonary fibrosis (IPF) at a single medical center between March 2006 and the end of December 2013. Survival was followed through 2015.

RESULTS:

A total of 17 lung transplantations were performed for silicosis among 342 lung transplantations (4.9%) during the study period. We observed non-statistically significant survival advantage (hazard ratio 0.6; 95%CI 0.24-1.55) for those undergoing lung transplantation for silicosis relative to IPF patients undergoing lung transplantation during the same period.

CONCLUSIONS:

Within the limits of a small sample, survival in silicosis patients following lung transplantation was not reduced compared to IPF. Am. J. Ind. Med. 60:248-254, 2017. © 2017 Wiley Periodicals, Inc.

• Authors: Dror Rosengarten, Benjamin D Fox, Elizabeth Fireman, Paul D Blanc, Victoria Rusanov, Oren Fruchter, Yael Raviv, Osnat Shtraichman, Milton Saute, Mordechai R Kramer
• Journal: American journal of industrial medicine (Am J Ind Med) Vol. 60 Issue 3 Pg. 248-254 (Mar 2017) ISSN: 1097-0274 [Electronic] United States
• PMID: 28145560 (Publication Type: Evaluation Study, Journal Article)
• Copyright: © 2017 Wiley Periodicals, Inc.

Topics

• Female
• Humans
• Idiopathic Pulmonary Fibrosis (surgery)
• Lung Transplantation (mortality)
• Male
• Middle Aged
• Proportional Hazards Models
• Retrospective Studies
• Silicosis (etiology, surgery)
• Survival Rate
• Treatment Outcome